Man Group plc Buys Shares of 130,379 InfuSystem Holdings, Inc. $INFU

Key Points

• Man Group plc acquired 130,379 InfuSystem shares worth approximately $1.26 million, giving it a 0.65% stake. Institutional investors collectively own 71.13% of the company, with several major funds initiating positions during the second quarter.
• B. Riley raised its InfuSystem price target to $20 from $12 while maintaining a Buy rating. Analysts’ consensus is “Moderate Buy,” with an average price target of $16.67.
• InfuSystem authorized a $20 million share buyback, allowing repurchases of up to 10.2% of outstanding shares. The stock recently opened at $12.14, near its 52-week high of $12.97.

Man Group plc bought a new stake in InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 130,379 shares of the company's stock, valued at approximately $1,258,000. Man Group plc owned 0.65% of InfuSystem at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in INFU. BlackRock Inc. purchased a new position in InfuSystem during the second quarter valued at approximately $15,299,000. Heartland Advisors Inc. purchased a new stake in InfuSystem in the 2nd quarter worth approximately $6,755,000. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in InfuSystem in the 2nd quarter worth approximately $4,719,000. Meros Investment Management LP acquired a new stake in shares of InfuSystem during the 2nd quarter valued at $4,525,213. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of InfuSystem by 220.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 449,348 shares of the company's stock valued at $4,655,000 after buying an additional 308,974 shares during the period. 71.13% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, B. Riley Financial restated a "buy" rating and set a $20.00 price target (up from $12.00) on shares of InfuSystem in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $16.67.

InfuSystem Stock Performance

INFU opened at $12.14 on Thursday. The stock has a 50-day moving average of $10.66 and a 200-day moving average of $9.78. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. InfuSystem Holdings, Inc. has a 52-week low of $7.29 and a 52-week high of $12.97. The company has a market cap of $245.01 million, a PE ratio of 202.37 and a beta of 1.50.

InfuSystem declared that its board has authorized a share buyback program on Tuesday, May 19th that permits the company to buyback $20.00 million in shares. This buyback authorization permits the company to buy up to 10.2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.

InfuSystem Company Profile

InfuSystem Holdings Inc is a medical technology company that specializes in the rental, management and servicing of infusion pumps and associated devices used primarily for outpatient infusion therapy. The company provides a comprehensive suite of services that includes equipment delivery, setup and retrieval, preventive and corrective maintenance, reprocessing and quality assurance. InfuSystem's offerings are designed to help hospitals, ambulatory surgery centers, oncology clinics and private infusion suites streamline clinical operations and maintain compliance with safety standards.

In addition to pump rental and repair services, InfuSystem has expanded into remote patient monitoring solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.